Aquestive Therapeutics’ (AQST) “Outperform” Rating Reiterated at Leerink Partners

Leerink Partners restated their outperform rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research report released on Monday, Benzinga reports. They currently have a $12.00 price target on the stock, up from their previous price target of $10.00.

A number of other analysts have also recently commented on AQST. JMP Securities reaffirmed a market outperform rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Monday, August 12th. HC Wainwright upped their price target on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the company a buy rating in a research report on Monday. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of Buy and a consensus target price of $8.67.

Aquestive Therapeutics Stock Down 2.3 %

Shares of Aquestive Therapeutics stock opened at $4.68 on Monday. Aquestive Therapeutics has a twelve month low of $1.25 and a twelve month high of $6.23. The stock has a market cap of $426.06 million, a price-to-earnings ratio of -11.14 and a beta of 2.84. The company’s fifty day moving average is $4.31 and its 200 day moving average is $3.68.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.08. The firm had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period last year, the company posted ($0.10) EPS. As a group, equities analysts anticipate that Aquestive Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its position in Aquestive Therapeutics by 58.9% in the 3rd quarter. SG Americas Securities LLC now owns 25,619 shares of the company’s stock worth $128,000 after purchasing an additional 9,496 shares in the last quarter. Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics in the 2nd quarter worth about $27,000. PFG Investments LLC grew its position in Aquestive Therapeutics by 22.9% in the 2nd quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock worth $153,000 after purchasing an additional 11,000 shares in the last quarter. Financial Advocates Investment Management grew its position in Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after purchasing an additional 14,000 shares in the last quarter. Finally, Lazard Asset Management LLC grew its position in Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after purchasing an additional 15,601 shares in the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.